Evolus (EOLS) Stock Forecast & Price Target

Evolus Inc reported a 29.4% year-over-year increase in total net revenue, rising to $78.9 million in 4Q23, primarily driven by a higher volume of Jeuveau sales. The company saw significant account growth, with approximately 830 new accounts purchasing Jeuveau, indicating strong market demand and engagement. Furthermore, the upcoming launch of the Evolysse fillers is anticipated to contribute an estimated 8-10% of total revenue for FY 2025, alongside management’s confidence in expanding beyond initial accounts, creating potential for future revenue growth.

Evolus Inc. reported a GAAP net loss of $6.8 million for the fourth quarter of 2023, translating to a loss per share of $0.11, which exceeded internal estimates but fell short of broader market expectations. The company's non-GAAP operating performance also indicated financial strain, as it posted a non-GAAP operating loss per share of $0.07, highlighting ongoing challenges in achieving profitability. Additionally, fundamental operational risks, such as reliance on third-party suppliers, increasing operating expenses for marketing and product development, and competitive pressures within the cash-pay aesthetic market contribute to a negative outlook for Evolus's stock.